Evaluation of an Alternative Schedule for CRLX101 Alone in Combination With Bevacizumab and in Combination With mFOLFOX6 in Subjects With Advanced Solid Tumor Malignancies

Trial Profile

Evaluation of an Alternative Schedule for CRLX101 Alone in Combination With Bevacizumab and in Combination With mFOLFOX6 in Subjects With Advanced Solid Tumor Malignancies

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs Camptothecin (Primary) ; Bevacizumab; Fluorouracil; Folic acid; Oxaliplatin
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Cerulean Pharma; NewLink Genetics Corporation
  • Most Recent Events

    • 18 Apr 2017 Planned End Date changed from 1 Jan 2017 to 1 Dec 2017.
    • 18 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Oct 2017.
    • 18 Apr 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top